Authors
Yan Ouyang, Hong Ren, Weiming Wang, Na Liu, Beiyan Bao, Hua Li, Xiaoling Xiong, Jian Li, Duolao Wang, Qinjie Weng, Chaohui Wang, Jingyuan Xie, Nan Chen
Published in
American journal of kidney diseases : the official journal of the National Kidney Foundation. Nov 07, 2026. Epub Nov 07, 2026.
Abstract
B-cell dysregulation contributes to IgA nephropathy (IgAN). Rituximab (RTX) targets CD20-positive B cells, but its efficacy in adults with IgAN receiving stable renin-angiotensin system inhibitor (RASI) therapy remains uncertain. This study sought to evaluate the efficacy and safety of RTX combined with RASI therapy compared with RASI therapy alone.
Multicenter, randomized, controlled trial.
Chinese adults with biopsy-proven IgAN across 10 centers, with 24-hour urine total protein (UTP) >1 g/day despite ≥3 months RASI therapy, and blood pressure <130/80 mmHg.
RTX plus RASI versus RASI alone for 12 months OUTCOMES: Primary: 24-hour UTP change at month 12. Secondary continuous: changes in 24-hour UTP at month 6 and in eGFR and serum Gd-IgA1 at month 12. Secondary categorical: ≥50% reduction in 24-hour UTP at months 6 and 12, ≥50% eGFR decline or doubling of serum creatinine, and ESKD.
adverse events, serious adverse events, and infections. Exploratory analyses examined outcomes through month 24.
Among the 106 participants randomized (53 per group), 24-hour UTP change at 12 months was similar between groups (adjusted GMR, 1.05; 95% CI, 0.80-1.36). Median change of 24-hour UTP was -0.21 g/day for RTX and -0.26 g/day for RASI. No statistically significant differences were observed in eGFR (adjusted mean difference, 3.80 mL/min/1.73 m2; 95% CI, -0.47 to 8.06), Gd-IgA1 (adjusted GMR, 1.04; 95% CI, 0.87-1.24), or the proportion achieving a ≥50% reduction in 24-hour UTP (15.1% vs 20.8%). Adverse events occurred at similar rates between two groups; no events of ≥50% eGFR decline, doubling of serum creatinine, or ESKD occurred during the 12-month treatment period. These findings were consistent with analyses that included outcome data through month 24.
The follow-up period was relatively short, and only Asian patients were enrolled.
No additional reduction in proteinuria or preservation of kidney function was observed with the addition of RTX to optimized RASI-based therapy in patients with IgAN.
Grants from government (National Key Research and Development Program, Major International [Regional] Joint Research Program of China, National Natural Science Foundation of China, National Facility for Translational Medicine [Shanghai], Shanghai 'Rising Stars of Medical Talent' Youth Development Program), academic (Shanghai Shenkang Hospital Development Center), and non-profit (International Society of Nephrology) sources.
PMID:
42998785
Bibliographic data and abstract were imported from PubMed on 08 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 51
- Comments 0